Response to Letter to the Editor by Anders et al.

Toxicology and Applied Pharmacology

Volumn 248, Issue 1, 2010, Pages 65-67

  Evans, Marina V ^a   Caldwell, Jane C ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE; METHYL CHLORIDE;

DNA DAMAGE; ENZYME ACTIVITY; FEMALE; HYPOTHESIS; LETTER; MOUSE; NONHUMAN; TOXICOKINETICS; XENOBIOTIC METABOLISM;

EID: 77956412144     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.07.011     Document Type: Letter

References (14)

1. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 1987, 87(2):185-205. 1987 Feb.
2. Atkins W.M. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu. Rev. Pharmacol. Toxicol. 2005, 45:291-310.
3. Chowdhury G., Calcutt M.W., Guengerich F.P. Oxidation of N-Nitrosoalkylamines by human cytochrome P450 2A6: sequential oxidation to aldehydes and carboxylic acids and analysis of reaction steps. J. Biol. Chem. 2010, 285(11):8031-8044. 2010 Mar 12.
4. Collom S.L., Laddusaw R.M., Burch A.M., Kuzmic P., Perry M.D., Miller G.P. CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. Biol. Chem. 2008, 283(6):3487-3496. 2008 Feb 8.
5. Crump K.S., Hoel D.G. Low-dose linearity-when should it be invoked? Presentation at 2010 2010, Society of Toxicology Meeting, Salt Lake City, Utah.
6. Crump K.S., Chiu W.A., Subramaniam R.P. Issues in using human variability distributions to estimate low-dose risk. Environ. Health Perspect. 2009, 118(3):387-393. 2010 Mar.
7. Crump K.S., Chen C., Chiu W.A., Louis T.A., Portier C.J., Subramaniam R.P., White P.S. (2010) What role for biologically based dose-response models in estimating low-dose risk?. Environ. Health Perspect. 2010, 118(5):585-588. May.
8. David R.M., Clewell H.J., Gentry P.R., Covington T.R., Morgott D.A., Marino D.J. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul. Toxicol. Pharmacol. 2006, 45(1):55-65. 2006 Jun.
9. Evans M.V., Caldwell J.C Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice. Toxicol. Appl. Pharmacol. 2010, 244(3):280-290.
10. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models:evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998, 37(12):4137-4147. 1998 Mar 24.
11. Landi S., Naccarati A., Ross M.K., Hanley N.M., Dailey L., Devlin R.B., Vasquez M., Pegram R.A., DeMarini D.M. Induction of DNA strand breaks by trihalomethanes in primary human lung epithelial cells. Mutat. Res. 2003, 538(1-2):41-50. 2003 Jul 8.
12. Reitz R.H., Mendrala A.L., Guengerich F.P. In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. Toxicol. Appl. Pharmacol. 1989, 97:230-246.
13. Watanabe K., Guengerich F.P. Limited reactivity of formyl chloride with glutathione and relevance to metabolism and toxicity of dichloromethane. Chem. Res. Toxicol. 2006, 19(8):1091-1096. 2006 Aug.
14. Watanabe K., Liberman R.G., Skipper P.L., Tannenbaum S.R., Guengerich F.P. Analysis of DNA adducts formed in vivo in rats and mice from 1,2-dibromoethane,1,2-dichloroethane, dibromomethane, and dichloromethane using HPLC/accelerator mass spectrometry and relevance to risk estimates. Chem. Res. Toxicol. 2007, 20(11):1594-1600. 2007 Nov.